Alamar Biosciences, Inc. — Blitz Index 53 (C)
Alamar Biosciences scores 53 — proteomics revenue up 195% with margins improving alongside, held back by a seven-month public history and a patent suit aimed at the platform itself.
Last re-scored: November 4, 2026.
Confidence: Medium · Category: frontier
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 19 / 25 | Revenue Q2 +82%, Q3 +68%, FY2025 +195%, with FY2026 guidance raised (+64%) — the fastest speed in its scoring batch |
| B · Moat | 29 / 60 | Data and ecosystem effects (B1 6) plus partner distribution (B2 7) and an improving margin (B4 8, gross margin 61.5%) — a mid-sized moat, still forming |
| C · Creative destruction | 10 / 15 | High-sensitivity proteomics displacing lower-resolution protein measurement in research and biomarker discovery — a real substitution, still research-use only |
| D · BlitzFailing | −5 | Effectively debt-free with $231.5M of cash (D1 0); academic and government funding dependence (D2 −2); the Olink patent suit, which could threaten the NULISA platform itself (D4 −3) |
Think we scored it wrong? Score it yourself →
Radar axes (0–100): Moat 48.3 · Speed 76.0 · Creative 66.7.
Watch item
Gates: G1 ✓ (confirmed — growth exploding: Q2 +82%, Q3 +68%, consumables +147% in Q2) · G2 ✓ (confirmed — proteomics extrapolates to ~$134–154B by 2036, over 100× the bar). 12 points below the 65-point threshold — first score. No FLAG: deductions of only 5. Watch: the Olink patent suit, whether the growth survives off a $25M base, and whether research funding holds.
Strengths
- Explosive growth: Q2 +82%, Q3 +68%, FY2025 +195%, FY2026 guidance of $121–123M raised (+64%)
- Consumable pull: Q2 +147%, Q3 +79%, 53% of revenue, ~$529k of pull-through per instrument
- Margins improving with growth: gross margin 56% (FY2025) → 60% (Q2) → 61.5% (Q3)
- Large-project proof: UK Biobank 80,000 samples, GSK 60,000+ samples, ADDI/Gates 140,000+ samples
- Debt-free balance sheet: $231.5M of cash, $197.8M of net IPO proceeds
Concerns
- Olink patent suit in progress (filed 2023, amended complaint 2026-04) — losing could threaten the platform's existence
- Research-use limits: no FDA clinical approval, and a clinical-diagnostics move needs separate clearance
- Dependence on academic and government research funding — a risk the company names itself
- Operating losses persist: Q2 −$13.5M, Q3 net loss −$13.3M, operating expenses up 89% YoY
- Seven months of public history — the trajectory is short and the base is low ($25M)
Research notes
Thesis: the fastest speed in its batch, on the shortest track record
Alamar Biosciences enters the BlitzLab record with a first scoring of 53 out of 100, grade C, built from Speed 19 out of 25, Moat 29 out of 60, Creative Destruction 10 out of 15, and deductions of 5. The total sits 12 points below the 65-point line, and the shape of the score is the story: speed converts to 76.0 and creative destruction to 66.7, while the moat converts to only 48.3. This is the proteomics company — trailing-twelve-month revenue of about $114.0 million — that went public in April 2026 and has since grown 82% in the second quarter and 68% in the third, with the gross margin improving alongside, from 56% to 61.5%. The balance sheet is effectively debt-free with $231.5 million of cash. The discount is time: seven months of public history on a $25 million base, and a patent suit from Olink that aims at the NULISA platform itself.
The gates: both pass — and the market ceiling is not close
Gate 1, two pieces of product-market-fit evidence for a growth company, passes on a confirmed basis. Revenue growth is explosive — Q2 +82%, Q3 +68% — and consumables, the repeat-purchase engine, grew 147% in the second quarter and 79% in the third, reaching 53% of revenue. Gate 2, a ten-year market ceiling at least ten times current revenue, passes as a confirmed verdict: proteomics extrapolates to roughly $134–154 billion by 2036, more than a hundred times the bar. The fourth quarter of 2026 has not been reported at T, and its reporting date is unconfirmed — it is not a company-confirmed date and must not be presented as one — and no outcome is anticipated here. That is the balance of the record at T: the fastest speed in its batch, a margin that improves as it grows, and a lawsuit that matters more than the score — if Olink wins, the platform itself is at stake.
What the business is: instruments that sell consumables
Alamar Biosciences sells precision proteomics — the measurement of hundreds of proteins from a blood sample — through its NULISA panels and ARGO system. The business model is the classic instrument-and-consumable razor: the ARGO instrument is placed with a customer, and the customer then buys NULISA consumables repeatedly. The repeat purchase is visible in the numbers: consumables were $15.5 million in the second quarter, up 147% year on year and 53% of revenue, and $17.8 million in the third quarter, up 79%. Pull-through was about $529,000 of consumables per installed instrument per year in 2025. The customer base is more than 300 customers in 25 countries with more than 100 cumulative installations, and the scientific record is growing with it — more than 200 papers and posters, four times the prior year. The large cohort projects are the proof of adoption: UK Biobank's 80,000 samples, due to complete by the end of 2027, GSK's 60,000-plus samples, and the ADDI/Gates project's 140,000-plus samples. Biopharma became the largest customer group in the third quarter, at 49% of revenue.
Why it scored 53: the fastest speed in its batch
Speed is 19 out of 25, converting to 76.0. Growth (A1, 9 of 10) is the strongest single item: revenue rose from $25.1 million in fiscal 2024 to $74.2 million in fiscal 2025, up 195%, then $26.0 million in the first quarter, $29.4 million in the second (up 82%) and $33.5 million in the third (up 68%), with fiscal 2026 guidance raised to $121–123 million, up 64% year on year. The point is held back only by the low base and the seven-month public track record. Capital speed (A2, 4 of 5) rests on the April 2026 IPO — 12,937,500 shares at $17.00, $219.9 million gross and $197.8 million net — plus cash of $231.5 million at the end of September and a $60 million credit facility with a $40 million accordion, against a quarterly burn of about $25 million. Hiring (A3, 2 of 5) is the weakest speed item because the 2026 headcount is undisclosed and no hiring blitz can be verified. Share momentum (A4, 4 of 5) is the cohort pipeline and the literature record. The moat is 29 out of 60 (48.3): network effects 6, distribution 7, market size 8 and gross margin 8, the last on a gross margin that improved from 56% in fiscal 2025 to 60% in the second quarter and 61.5% in the third. Creative destruction is 10 out of 15: the displacement of traditional immunoassays by multiplex proteomics (4), adoption spreading through the research community (3) and the per-protein cost advantage of multiplexing (3).
The risks: a lawsuit aimed at the platform itself
The deductions total only 5, and one item dominates them. Regulation and social cost (D4, minus 3) is the Olink patent suit: Olink Proteomics, part of Thermo Fisher, sued in 2023 and filed an amended complaint in April 2026 alleging that the NULISA platform infringes its patents. A loss would put the platform itself at stake, which is why the suit matters more than the three points it costs. Revenue quality (D2, minus 2) reflects two limits: the products are research-use only, with no FDA clinical approval, so conversion to clinical diagnostics needs separate authorisation; and the company depends on academic and government research funding, which it names as a core risk, with spending cuts a live threat. The balance sheet is the offset: debt (D1) is zero, effectively debt-free, with the IPO proceeds behind the cash pile, and governance (D3) is zero only because no dual-class or founder-control structure was disclosed in the sources reviewed. The operating reality behind the growth is still loss-making — an operating loss of $13.5 million in the second quarter and a net loss of $13.3 million in the third, with operating expenses up 89% year on year — so the margin improvement has not yet reached the bottom line.
What would change the score
The single most important event is the Olink suit: a favourable outcome would remove the platform-level risk, while an adverse one would hit the score far beyond the current three points. The second is time — the seven-month public record lengthening into a multi-year growth trajectory, which is what the growth item's withheld tenth point is waiting for. Disclosure would help directly: a published headcount would let hiring and productivity be scored on evidence rather than conservatively, and disclosure of the governance structure would resolve the zero that currently rests on absence of evidence. Commercially, the tests are delivery of the raised $121–123 million guidance for fiscal 2026, completion of the UK Biobank project by the end of 2027, and any step toward clinical authorisation that would open the diagnostic market the research-use-only label currently closes. The cash position gives roughly nine quarters of runway at the current burn, so the funding question is not immediate — the question is whether the burn narrows as the margin keeps rising.
More Frontier companies
Other Frontier names on the Blitz Index, highest score first: Rocket Lab (62/B), Tesla (62/B), Illumina, Inc. (61/B).
Next earnings
Q4 2026 · Expected
Coverage
Alamar Biosciences, Inc. · Next earnings unconfirmed at scoring · Score 53 · Grade C
Embed this score
Copy the HTML below to show this score on your site. The badge links back to this page and updates automatically when the score changes.
Preview:
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.